This material is intended for reference by healthcare professionals only

GLP-1 Receptor Agonists for Weight Loss: 7 Key Questions from Mechanism to Clinical Practice

Introduction: Obesity Has Become a Global Public Health Challenge Obesity is no longer simply a "weight problem" but a chronic metabolic disease requiring long-term management. According to the Global Burden of Disease (GBD) study published in The New England Journal of Medicine, between 1990 and 2015, the number of deaths worldwide related to overweight and obesity increased by 28.3%, and obesity is closely associated with cardiovascular disease, type 2 diabetes, multiple types of cancer, and obstructive sleep apnea (OSA), among others [1]. The World Obesity Federation predicts that, without effective intervention, the global population with overweight/obesity will exceed half of the world's population by 2035. In recent years, weight-loss medications represented by glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have brought important advances to obesity management. Drugs such as semaglutide 2.4 mg and tirzepatide have demonstrated significant weight-loss effects and cardiometabolic benefits in clinical trials, attracting widespread attention from both the academic community and the public. This article summarizes 7 key questions that physicians need to understand in clinical decision-making.

I. How Do GLP-1 RAs Achieve Weight Loss?

GLP-1 is an incretin secreted by enteroendocrine L cells in the ileum after eating. Native GLP-1 has an extremely short half-life (about 1-2 minutes) and is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Pharmaceutical GLP-1 RAs extend the half-life through structural modification, enabling once-weekly dosing. Their weight-loss mechanisms involve multiple targets: Central action: crossing the blood-brain barrier to act on the hypothalamic appetite regulation center, enhancing satiety and reducing hunger, thereby lowering energy intake; Delayed gastric emptying: slowing the rate at which gastric contents enter the small intestine, prolonging postprandial fullness; Reduced ectopic fat deposition: improving visceral fat and liver fat content. Tirzepatide is a GIP/GLP-1 dual receptor agonist, adding glucose-dependent insulinotropic polypeptide (GIP) receptor agonism on top of the GLP-1 pathway.

II. How Much Weight Loss Is Actually Achieved?

Semaglutide 2.4 mg: The STEP 1 study enrolled 1961 adults with BMI ≥30 (or ≥27 with weight-related comorbidities) and without diabetes. On the basis of lifestyle intervention, once-weekly subcutaneous injection of semaglutide 2.4 mg resulted in an average weight loss of 14.9% after 68 weeks, compared with only 2.4% in the placebo group; more than one-third of participants lost ≥20% of body weight [2]. Tirzepatide: The SURMOUNT-1 study enrolled 2539 adults with obesity or overweight. At 72 weeks, the tirzepatide 5 mg, 10 mg, and 15 mg groups lost an average of 15.0%, 19.5%, and 20.9% of body weight, respectively, compared with 3.1% in the placebo group; in the 15 mg group, about 57% of participants lost ≥20% of body weight [3]. In the population with type 2 diabetes, the STEP 2 study showed that semaglutide 2.4 mg treatment for 68 weeks resulted in weight loss of approximately 9.6%, significantly superior to placebo [4]. It should be emphasized that the above data were all obtained on the basis of lifestyle intervention; the medication is not synonymous with "effortless weight loss." Overview of Key Clinical Trial Data
StudyDrugPopulationTreatment DurationWeight Change (Treatment Group)Weight Change (Placebo)
STEP 1Semaglutide 2.4 mgObesity/overweight, without diabetes68 weeks-14.9%-2.4%
STEP 2Semaglutide 2.4 mgObesity/overweight, with type 2 diabetes68 weeks-9.6%-3.4%
SURMOUNT-1Tirzepatide 15 mgObesity/overweight, without diabetes72 weeks-20.9%-3.1%
SELECTSemaglutide 2.4 mgObesity/overweight, with cardiovascular diseaseMedian 34-46 months20% reduction in MACE risk—

III. Beyond Weight Loss, What Other Cardiometabolic Benefits Exist?

Cardiovascular benefits: The SELECT study enrolled 17,604 overweight/obese adults with established cardiovascular disease but without diabetes, with a median follow-up of 34-46 months. In the semaglutide 2.4 mg group, the risk of major adverse cardiovascular events (MACE, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) was reduced by 20% compared with placebo (HR 0.80, 95% CI 0.72-0.90) [5]. This is cardiovascular outcome evidence of major significance in the field of weight-loss medications. Metabolic and other benefits: GLP-1 RAs can improve glycemic control, blood pressure, and lipid profiles, reduce C-reactive protein levels, and have shown potential benefits in OSA, nonalcoholic steatohepatitis (NASH/MASH), chronic kidney disease, and other areas. Some studies also suggest possible improvements in osteoarthritis symptoms and heart failure-related indicators.

IV. Who Is Eligible? Who Is Not?

Based on current evidence and mainstream guidelines, the eligible population mainly includes: adults with BMI ≥ 30 kg/m² (obesity); or adults with BMI ≥ 27 kg/m² (overweight) and at least one weight-related comorbidity (such as hypertension, dyslipidemia, type 2 diabetes, OSA, etc.). The following populations should avoid or use with caution: patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); pregnant and breastfeeding women; those with severe gastrointestinal disease or a history of pancreatitis require careful assessment; those allergic to drug components. Before treatment, patients' weight history, comorbidities, medication adherence, and reproductive plans should be fully assessed, and secondary obesity should be ruled out.

V. How Are Adverse Reactions Managed?

Gastrointestinal reactions are the most common adverse events, mostly mild to moderate and dose-dependent: nausea, vomiting, diarrhea, constipation: usually occur during dose escalation and gradually resolve over time; management strategies: slow titration, small frequent meals, avoidance of high-fat diets, ensuring fluid intake; if necessary, pause dose increases or provide symptomatic treatment. Rare but important adverse events to watch for include pancreatitis, gallbladder disease (cholelithiasis), and progression of diabetic retinopathy (in those with pre-existing proliferative diabetic lesions). Clinicians should inform patients to seek medical attention promptly if persistent severe abdominal pain occurs.

VI. Why Does Weight Rebound After Stopping the Drug?

Obesity is a chronic, relapsing disease. The STEP 4 study showed that after 20 weeks of semaglutide 2.4 mg treatment, those who continued the drug experienced a further 7.9% weight loss at 68 weeks compared with randomization, while those switched to placebo regained 6.9% of their weight, a significant difference between the two groups [6]. This suggests that the appetite and metabolic regulation brought about by the drug require continuous maintenance, and after discontinuation, physiological compensatory mechanisms can drive weight regain. Therefore, in clinical communication, obesity management should be positioned as "long-term treatment" rather than a "short-term course," and a sustainable follow-up and maintenance plan should be developed jointly with patients.

VII. Clinical Practice Recommendations

Full informed communication: explain to patients the role of the medication, expected effects, common adverse reactions, and the necessity of long-term use; combine with lifestyle intervention: medication should serve as an adjunct to dietary control, physical activity, and behavioral interventions; standardized titration and monitoring: gradually increase the dose according to the label, and regularly follow up on weight, waist circumference, blood pressure, blood glucose, lipids, and adverse reactions; set reasonable goals: a 5%-10% weight loss can bring significant metabolic improvement, and some patients can achieve 15%-20% or more; multidisciplinary collaboration: complex cases can be managed jointly with endocrinology, nutrition, cardiology, and surgery (for metabolic surgery evaluation).

Summary

GLP-1 receptor agonists provide a powerful tool for the management of obesity and related metabolic diseases. Drugs such as semaglutide and tirzepatide, while significantly reducing weight, have demonstrated clear cardiovascular benefits and are reshaping the landscape of obesity treatment. However, medications are not a panacea; only by strictly adhering to indications, standardizing adverse reaction management, and maintaining long-term comprehensive intervention can patients truly benefit.

References

[1] GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13-27. PMID: 28604169.[2] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.[3] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.[4] Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 34052039.[5] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37356055.[6] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 34313713.Disclaimer: This article is based on publicly published clinical research and data from authoritative institutions, and is intended solely for academic reference by healthcare professionals. It does not constitute promotion or prescribing recommendations for any specific drug. The drugs mentioned in this article should be used under the guidance of a physician, and specific treatment regimens should follow the product label and clinical guidelines. Conflicts of interest: This article was produced by Sun Biolotus (Beijing) Medical Technology Co., Ltd., and did not receive sponsorship or intervention from any third-party company. All data in this article are derived from publicly available academic literature. © 2026 Sun Biolotus (Beijing) Medical Technology Co., Ltd.